Search

Your search keyword '"Escudier, Bernard"' showing total 1,696 results
Start Over Author "Escudier, Bernard"
1,696 results on '"Escudier, Bernard"'

204. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

Author

Wood, Christopher, Srivastava, Pramod, Bukowski, Ronald, Lacombe, Louis, Gorelov, Andrei I, Gorelov, Sergei, Mulders, Peter, Zielinski, Henryk, Hoos, Axel, Teofilovici, Florentina, Isakov, Leah, Flanigan, Robert, Figlin, Robert, Gupta, Renu, and Escudier, Bernard

Published
2008
Full Text
View/download PDF

209. Local recurrence after radical nephrectomy for kidney cancer: management and prediction of outcomes. a multi-institutional study

Author

Paparel, Philippe, Bigot, Pierre, Matillon, Xavier, Bensalah, Karim, Salomon, Laurent, Baumert, Hervé, Bastide, Cyril, Thuret, Rodolphe, Karsenty, Gilles, Long, Jean Alexandre, Ammi, Myriam, Bessede, Thomas, Bin, Sylvie, Roux, Adeline, Escudier, Bernard, Leclercq, Nathalie Rioux, Pignot, Géraldine, Soulie, Michel, and Patard, Jean-Jacques

Published
2014
Full Text
View/download PDF

212. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Author

Choueiri, Toni K., primary, Powles, Thomas, additional, Burotto, Mauricio, additional, Escudier, Bernard, additional, Bourlon, Maria T., additional, Zurawski, Bogdan, additional, Oyervides Juárez, Victor M., additional, Hsieh, James J., additional, Basso, Umberto, additional, Shah, Amishi Y., additional, Suárez, Cristina, additional, Hamzaj, Alketa, additional, Goh, Jeffrey C., additional, Barrios, Carlos, additional, Richardet, Martin, additional, Porta, Camillo, additional, Kowalyszyn, Rubén, additional, Feregrino, Juan P., additional, Żołnierek, Jakub, additional, Pook, David, additional, Kessler, Elizabeth R., additional, Tomita, Yoshihiko, additional, Mizuno, Ryuichi, additional, Bedke, Jens, additional, Zhang, Joshua, additional, Maurer, Matthew A., additional, Simsek, Burcin, additional, Ejzykowicz, Flavia, additional, Schwab, Gisela M., additional, Apolo, Andrea B., additional, and Motzer, Robert J., additional

Published
2021
Full Text
View/download PDF

213. The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma

Author

Rassy, Elie, primary, Cerbone, Luigi, additional, Auclin, Edouard, additional, Benchimoll-Zouari, Axelle, additional, Flippot, Ronan, additional, Alves Costa Silva, Carolina, additional, Colomba, Emeline, additional, Geraud, Arthur, additional, Guida, Annalisa, additional, Mir, Olivier, additional, Combarel, David, additional, Paci, Angelo, additional, Escudier, Bernard, additional, and Albiges, Laurence, additional

Published
2021
Full Text
View/download PDF

215. Association of cabozantinib residual concentration (Ctrough) and blood clearance (Cl/F) with toxicity (tox) and progressive disease (PD) in metastatic renal cell carcinoma (mRCC) patients (pts): Results from a monocentric pharmacokinetics (PK) study.

Author

Cerbone, Luigi, primary, Combarel, David, additional, Foulon, Stéphanie, additional, Geraud, Arthur, additional, Alves, Carolina, additional, Colomba, Emeline, additional, Carril, Lucia, additional, Derosa, Lisa, additional, Flippot, Ronan, additional, Mir, Olivier, additional, Escudier, Bernard, additional, Paci, Angelo, additional, and Albiges, Laurence, additional

Published
2021
Full Text
View/download PDF

217. Safety and efficacy of nivolumab in older patients (pts) with renal cell carcinoma: Results of a sub-group analysis of the GETUG-AFU 26 NIVOREN multicenter phase II study.

Author

Mourey, Loic, primary, Dalban, Cécile, additional, Negrier, Sylvie, additional, Chevreau, Christine, additional, Gravis, Gwenaelle, additional, Thibault, Constance, additional, Laguerre, Brigitte, additional, Barthelemy, Philippe, additional, Borchiellini, Delphine, additional, Gross-Goupil, Marine, additional, Geoffrois, Lionnel, additional, Rolland, Frederic, additional, Thiery-Vuillemin, Antoine, additional, Joly, Florence, additional, Ladoire, Sylvain, additional, Tantot, Florence, additional, Escudier, Bernard, additional, and Albiges, Laurence, additional

Published
2021
Full Text
View/download PDF

218. Association of statins and nivolumab activity in patients with metastatic renal cell carcinoma (mRCC): Results from the phase II nivoren—GETUG AFU 26 trial.

Author

Colomba, Emeline, primary, Flippot, Ronan, additional, Dalban, Cécile, additional, Negrier, Sylvie, additional, Chevreau, Christine, additional, Gravis, Gwenaelle, additional, Oudard, Stephane, additional, Laguerre, Brigitte, additional, Barthelemy, Philippe, additional, Gross Goupil, Marine, additional, Geoffrois, Lionnel, additional, Rolland, Frederic, additional, Thiery-Vuillemin, Antoine, additional, Joly, Florence, additional, Ladoire, Sylvain, additional, Tantot, Florence, additional, Escudier, Bernard, additional, and Albiges, Laurence, additional

Published
2021
Full Text
View/download PDF

219. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program

Author

Albiges, Laurence, primary, Fléchon, Aude, additional, Chevreau, Christine, additional, Topart, Delphine, additional, Gravis, Gwenaëlle, additional, Oudard, Stéphane, additional, Tourani, Jean M., additional, Geoffrois, Lionnel, additional, Meriaux, Emeline, additional, Thiery-Vuillemin, Antoine, additional, Barthélémy, Philippe, additional, Ladoire, Sylvain, additional, Laguerre, Brigitte, additional, Perrot, Valérie, additional, Billard, Anaïs, additional, Escudier, Bernard, additional, and Gross-Goupil, Marine, additional

Published
2021
Full Text
View/download PDF

222. Sorafenib in advanced clear-cell renal-cell carcinoma

Author

Escudier, Bernard; Eisen, Tim; Stadler, Walter M.; Szczylik, Cezary; Oudard, Stephane; Siebels, Michael

Subjects
Carcinoma, Renal cell -- Drug therapy
Abstract

A phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis in patients with advanced clear-cell renal-cell carcinoma was conducted. Results revealed that oral sorafenib therapy prolonged progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom first-line therapy had failed.

Published
2007

228. Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma

Author

Guida, Annalisa, primary, Le Teuff, Gwénaël, additional, Alves, Carolina, additional, Colomba, Emeline, additional, Di Nunno, Vincenzo, additional, Derosa, Lisa, additional, Flippot, Ronan, additional, Escudier, Bernard, additional, and Albiges, Laurence, additional

Published
2020
Full Text
View/download PDF

229. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade

Author

Motzer, Robert J., primary, Banchereau, Romain, additional, Hamidi, Habib, additional, Powles, Thomas, additional, McDermott, David, additional, Atkins, Michael B., additional, Escudier, Bernard, additional, Liu, Li-Fen, additional, Leng, Ning, additional, Abbas, Alexander R., additional, Fan, Jinzhen, additional, Koeppen, Hartmut, additional, Lin, Jennifer, additional, Carroll, Susheela, additional, Hashimoto, Kenji, additional, Mariathasan, Sanjeev, additional, Green, Marjorie, additional, Tayama, Darren, additional, Hegde, Priti S., additional, Schiff, Christina, additional, Huseni, Mahrukh A., additional, and Rini, Brian, additional

Published
2020
Full Text
View/download PDF

230. Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma

Author

Pal, Sumanta K., primary, Escudier, Bernard J., additional, Atkins, Michael B., additional, Hutson, Thomas E., additional, Porta, Camillo, additional, Verzoni, Elena, additional, Needle, Michael N., additional, Powers, Daniel, additional, McDermott, David F., additional, and Rini, Brian I., additional

Published
2020
Full Text
View/download PDF

231. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial

Author

Eisen, Tim, primary, Frangou, Eleni, additional, Oza, Bhavna, additional, Ritchie, Alastair W.S., additional, Smith, Benjamin, additional, Kaplan, Rick, additional, Davis, Ian D., additional, Stockler, Martin R., additional, Albiges, Laurence, additional, Escudier, Bernard, additional, Larkin, James, additional, Bex, Axel, additional, Joniau, Steven, additional, Hancock, Barry, additional, Hermann, Gregers G., additional, Bellmunt, Joaquim, additional, Hodgkinson, Elizabeth, additional, Stewart, Grant D., additional, Barber, Jim, additional, Brown, Janet, additional, McMenemin, Rhona, additional, Nathan, Paul, additional, Pickering, Lisa M., additional, Parmar, Mahesh K.B., additional, and Meade, Angela, additional

Published
2020
Full Text
View/download PDF

242. Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma.

Author

Cerbone, Luigi, Di Nunno, Vincenzo, Carril Ajuria, Lucia, Costa Silva, Carolina Alves, Colomba, Emeline, Guida, Annalisa, Salviat, Flore, Hirsch, Laure, Benchimol-Zouari, Axelle, Flippot, Ronan, Escudier, Bernard, and Albiges, Laurence

Subjects
RENAL cell carcinoma, OVERALL survival, IMMUNE checkpoint inhibitors, RETROSPECTIVE studies, NEOVASCULARIZATION inhibitors
Abstract

We performed a retrospective analysis on 56 patients with metastatic renal cell carcinoma who received at least 1 systemic treatment line after cabozantinib. Median OS after cabozantinib was 7.7 months, while median TTF after cabozantinib was 2.8 months. Further investigation is needed in this clinical context. Background: Cabozantinib, a potent multityrosine kinases inhibitor (TKI), has demonstrated overall survival (OS) benefit over everolimus in patients previously treated with VEGFR TKI for metastatic Renal Cell Carcinoma (mRCC). The efficacy of systemic treatments after cabozantinib failure has not been investigated. Materials and Methods: We conducted a retrospective study on patients receiving systemic treatment after cabozantinib failure in heavily pretreated patient with mRCC. We assessed Time to Treatment Failure (TTF), OS and objective response rate (ORR). Results: Among 150 patients treated with cabozantinib in our institution, 56 (37.3%) received subsequent systemic therapy and were eligible for the analysis. IMDC prognostic group was good, intermediate and poor in 11 (19.6%), 24 (42.9%) and 11 (19.6%) patients, respectively. Cabozantinib was administered mainly as a second (41.1%), or third (33.9%) line treatment. axitinib or immune-checkpoint inhibitors were the subsequent treatment in 18 (34.8%) patients for each everolimus (n:16, 28.6%), other angiogenesis inhibitors (n:4, 7.1%) TTF and OS from subsequent systemic therapy after cabozantinib failure were 2.8 months (95%CI 1.9-3.7) and 7.7 months (95%CI 4.4-10.8), respectively. ORR was 8.7% and 2 patients with axitinib and 2 patients treated with Immune checkpoint inhibitors achieved a partial response. Conclusion: Overall, activity of systemic therapies after cabozantinib was limited. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

249. Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma

Author

Gardie, Betty, Remenieras, Audrey, Kattygnarath, Darouna, Bombled, Johny, Lefèvre, Sandrine, Perrier-Trudova, Victoria, Rustin, Pierre, Barrois, Michel, Slama, Abdelhamid, Avril, Marie-Françoise, Bessis, Didier, Caron, Olivier, Caux, Frédéric, Collignon, Patrick, Coupier, Isabelle, Cremin, Carol, Dollfus, Hélène, Dugast, Catherine, Escudier, Bernard, Faivre, Laurence, Field, Michel, Gilbert-Dussardier, Brigitte, Janin, Nicolas, Leport, Yves, Leroux, Dominique, Lipsker, Dan, Malthieu, Félicia, McGilliwray, Barbara, Maugard, Christine, Méjean, Arnaud, Mortemousque, Isabelle, Plessis, Ghislaine, Poppe, Bruce, Pruvost-Balland, Christelle, Rooker, Serena, Roume, Joelle, Soufir, Nadem, Steinraths, Michelle, Tan, Min-Han, Théodore, Christine, Thomas, Luc, Vabres, Pierre, Van Glabeke, Emmanuel, Meric, Jean-Baptiste, Verkarre, Virginie, Lenoir, Gilbert, Joulin, Virginie, Deveaux, Sophie, Cusin, Veronica, Feunteun, Jean, Teh, Bin Tean, Paillerets, Brigitte Bressac-de, and Richard, Stéphane

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results